Top 5 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group

4. Argenx SE (NASDAQ:ARGX)

Redmile Group’s Stake Value: $220.6 million

Percentage of Redmile Group’s 13F Portfolio: 3.84%

Number of Hedge Fund Holders: 28

Argenx SE (NASDAQ:ARGX) is a biopharmaceutical company known for pipelining therapeutic solutions that utilize anti-bodies, and it is done with the company’s discovery platform called Simple Antibody. In November 2021, one of the focus drugs of the firm, called Efgartigimod, received orphan status from the FDA.

Among the hedge funds tracked by Insider Monkey, Julian Baker and Felix Baker’s placement agency, Baker Bros. Advisors, holds the most significant stake in Argenx SE (NASDAQ:ARGX) with 1.11 million shares worth $338.10 million, representing 1.48% of the fund’s portfolio.

Artisan Partners, an investment management firm, mentioned Argenx SE (NASDAQ:ARGX) in its quarter-two investor letter. Here is what it said:

“Argenx is a Dutch biotechnology company developing antibodybased therapies for autoimmune diseases and cancer. Commercial preparations are underway for the company’s FcRn drug efgartigimod, which is used to treat patients with severe autoimmune diseases. Discussions with health insurance payers have been positive, and the manufacturing/supply chain is well-positioned. Argenx appears to be not only first-in-class (a first mover) but also the best-inclass asset in a high value and competitive field of FcRn drugs. First-inclass drugs typically take the majority of market share, and with a best-in-class profile, Argenx could solidify a dominate market position.”